Cubist infectious news
Cubist announced goals to almost triple annual revenues by year end 2017 and move four product candidates in late-stage clinical trials at an investor meeting on June 11. Cubist said it hopes to generate $2 billion in annual revenues and $700 million in non-GAAP annual adjusted operating income. The company expects U.S. sales of antibiotic Cubicin daptomycin, a cyclic lipopeptide antibiotic, to grow to $1 billion by year end 2017, up from $698.8 million in 2011. Cubist also expects annual sales of gastrointestinal drug Entereg alvimopan to approach $100 million in the same period; the drug recorded U.S. sales of $2.5 million in 2011. Cubist reported $754 million in total revenue in 2011. Entereg is a mu opioid receptor ( OPRM1; MOR) antagonist. ...